Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    MOXR0916
Show Display Options
Rank Status Study
1 Recruiting A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Intervention: Drug: MOXR0916
2 Recruiting A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody;   Drug: Bevacizumab, a recombinant humanised anti-VEGF (vascular endothelial growth factor) monoclonal antibody;   Drug: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
3 Recruiting A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Condition: Urothelial Carcinoma
Interventions: Drug: MOXR0916;   Drug: Atezolizumab;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.